Standard operating procedure

Ongoing Monitoring & Review Procedure

How [Organisation Name] reviews patients on weight-loss medication at structured intervals, checks response, tolerability, adherence and ongoing suitability, applies stopping rules when an adequate response is not achieved, and operates a failsafe so that medication is never re-supplied without review.

For Weight Loss ClinicRef BS-WEI-SOP-005See a sample (PDF) →
£39.99
One-off purchase · no VAT · instant download
  • Instant download after checkout
  • Editable Microsoft Word (.docx)
  • Mapped to the CQC standards
  • Optional 3-monthly updates

What's inside

This standard operating procedure is fully drafted and structured, ready to brand and complete for your service. It covers:

  • 1. Purpose
  • 2. Scope
  • 3. Definitions and abbreviations
  • 4. Responsibilities
  • 5. Procedure
  • 6. Records
  • 7. Related documents
  • 8. Review and version control
  • 9. Disclaimer

Legislation & standards it maps to

  • Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 - Regulation 12 (Safe care and treatment) and Regulation 17 (Good governance)
  • National Institute for Health and Care Excellence (NICE) Clinical Guideline CG189 - Obesity: identification, assessment and management
  • National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance for weight-management medicines (the appraisal applicable to the prescribed product, for example semaglutide or tirzepatide for managing overweight and obesity)
  • The Summary of Product Characteristics (SmPC) for the specific weight-loss medicine prescribed
  • General Medical Council - Good practice in prescribing and managing medicines and devices (2021)
  • The Human Medicines Regulations 2012 (SI 2012/1916, as amended)
  • Data Protection Act 2018 and the UK General Data Protection Regulation (UK GDPR)

Who it applies to

All prescribers and clinical staff at [Organisation Name] involved in the ongoing monitoring, review, continuation or stopping of weight-loss pharmacotherapy - in particular glucagon-like peptide-1 (GLP-1) receptor agonists and related medicines - together with the administrative and dispensing-liaison staff who support review booking, supply reconciliation and the recall of patients who are overdue review.

Glossary

Plain-English explanations of the technical terms and legislation used in this document.

Adherence
How closely a patient follows the agreed treatment, including taking the right dose at the right time.
Adverse effect
An unwanted or harmful reaction caused by a medicine.
Baseline
A patient's starting measurement, such as their weight before treatment, used to judge later change.
Body mass index (BMI)
A measure of weight in relation to height (weight in kilograms divided by height in metres squared) used to classify a healthy weight, overweight or obesity.
Care Quality Commission (CQC)
The independent regulator of health and social care services in England.
Clinically meaningful response
A pre-set amount of weight loss within a set time that shows the medicine is working well enough to justify continuing it.
Contemporaneous
Written down at the time of, or very soon after, the event being recorded.
Contraindication
A specific situation or condition in which a medicine should not be used because it could cause harm.
Data Protection Act 2018
The UK law that, alongside the UK General Data Protection Regulation, governs how personal information must be handled.
DNA (did not attend)
A record that a patient missed a booked appointment without attending or cancelling.
General Medical Council (GMC)
The body that registers doctors in the UK and sets the standards they must follow.
General practitioner (GP)
A doctor who provides general medical care in the community and is usually a patient's main, ongoing doctor.
GLP-1 receptor agonist
A type of injectable medicine (for example semaglutide) used to support weight loss alongside diet and activity.
Health and Social Care Act 2008 (Regulated Activities) Regulations 2014
The regulations setting out the fundamental standards that providers of regulated care must meet.
Human Medicines Regulations 2012
The main UK law governing how medicines are licensed, supplied and prescribed.
Maintenance phase
The stage of treatment when a patient stays on a steady dose after the dose has been built up.
National Institute for Health and Care Excellence (NICE)
The body that produces evidence-based guidance on treatments and care for use across health services in England.
Near miss
An event that could have caused harm but did not, by chance or because it was caught in time.
Pancreatitis
Inflammation of the pancreas, which can cause severe abdominal pain and may be serious.
Percentage weight change
How much a patient's weight has gone up or down, shown as a percentage of their starting weight.
Pharmacotherapy
The treatment of a condition using medicines.
Prescriber
A healthcare professional legally allowed to decide on and authorise a patient's medicines.
Reconciliation (of supply)
Checking the amount of medicine a patient has received against the amount they should have used, to spot under-use, over-use or misuse.
Registered Manager
The person registered with the regulator as responsible for the day-to-day running of a service.
Regulated activity
A type of care or treatment the law requires a provider to register with the regulator to deliver.
Safeguarding
Protecting people's health, wellbeing and rights and keeping them safe from abuse, harm or neglect.
Semaglutide
A GLP-1 receptor agonist medicine used to help manage overweight and obesity.
Standard Operating Procedure (SOP)
A written, step-by-step instruction setting out how a particular task must be carried out consistently and safely.
Stopping rule
A pre-agreed reason that triggers a decision on whether to stop a medicine, such as not losing enough weight in the expected time.
Summary of Product Characteristics (SmPC)
The official, approved document for a medicine, setting out how it should be dosed and used, its warnings and what to monitor.
Technology appraisal
An assessment by the National Institute for Health and Care Excellence of whether a specific medicine or treatment should be used and for whom.
Tirzepatide
A medicine used to help manage overweight and obesity, acting on gut hormone pathways.
Titration
Gradually increasing a medicine's dose in planned steps until the right dose is reached, to reduce side effects.
Tolerability
How well a patient is able to cope with a medicine and its side effects.
UK General Data Protection Regulation (UK GDPR)
The UK's main data-protection law governing how personal information is collected and used.

How it works

  1. Buy securely with Stripe - instant, no VAT, no account needed.
  2. Download your editable Word file from the link we email you straight away.
  3. Complete the placeholders for your service, then have it approved before use.
  4. Add the optional updates subscription and we keep it current as guidance changes.

Related documents

PolicyGLP-1 Prescribing Policy£54.99
PolicyCardiovascular Assessment Policy£54.99
PolicyPsychological Screening Policy£54.99
PolicyInformed Consent Policy£54.99

Need the whole set?

Buy the full Weight Loss Clinic pack and save versus buying documents individually.

View the Weight Loss Clinic pack